{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T17:18:37Z","timestamp":1793035117676,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Fundaci\u00f3n CEU-Santander","award":["INDI20\/06"],"award-info":[{"award-number":["INDI20\/06"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-93844-2","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:52:57Z","timestamp":1742219577000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Study of the efficacy and the mechanism of action of lanreotide for the treatment of persistent diabetic macular edema"],"prefix":"10.1038","volume":"15","author":[{"given":"Ester","family":"Fernandez-Lopez","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mari Luz","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent M.","family":"Villar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Palacios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria C.","family":"Hernaez-Ortega","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amparo","family":"Navea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco Bosch","family":"Morell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"93844_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1167\/iovs.64.15.47","volume":"64","author":"T Yin Wong","year":"2023","unstructured":"Yin Wong, T. & Tan, T-E. The diabetic retinopathy pandemic and evolving global strategies: The 2023 Friedenwald lecture. Invest. Ophthalmol. Vis. Sci. 64, 47. https:\/\/doi.org\/10.1167\/iovs.64.15.47 (2023).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"93844_CR2","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.3390\/ijms21051682","volume":"21","author":"M Gomes-Porras","year":"2020","unstructured":"Gomes-Porras, M., C\u00e1rdenas-Salas, J. & Alvarez-Escol\u00e1, C. Somatostatin analogs in clinical practice: A review. Int. J. Mol. Sci. 21, 1682. https:\/\/doi.org\/10.3390\/ijms21051682 (2020).","journal-title":"Int. J. Mol. Sci."},{"key":"93844_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.2174\/157339912798829188","volume":"8","author":"GP Giuliari","year":"2012","unstructured":"Giuliari, G. P. Diabetic retinopathy: Current and new treatment options. Curr. Diabetes Rev. 8, 32\u201341 (2012).","journal-title":"Curr. Diabetes Rev."},{"key":"93844_CR4","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s13340-022-00571-4","volume":"13","author":"A Yuno","year":"2022","unstructured":"Yuno, A. et al. Advanced proliferative diabetic retinopathy and macular edema in acromegaly: A case report and literature review. Diabetol. Int. 13, 575\u2013579. https:\/\/doi.org\/10.1007\/s13340-022-00571-4 (2022).","journal-title":"Diabetol. Int."},{"key":"93844_CR5","doi-asserted-by":"publisher","first-page":"144","DOI":"10.3389\/fbioe.2020.00144","volume":"8","author":"R Amato","year":"2020","unstructured":"Amato, R. et al. Association of the somatostatin analog octreotide with magnetic nanoparticles for intraocular delivery: A possible approach for the treatment of diabetic retinopathy. Front. Bioeng. Biotechnol. 8, 144. https:\/\/doi.org\/10.3389\/fbioe.2020.00144 (2020).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"93844_CR6","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s10020-024-00824-9","volume":"30","author":"T Yang","year":"2024","unstructured":"Yang, T. et al. An update on chronic complications of diabetes mellitus: From molecular mechanisms to therapeutic strategies with a focus on metabolic memory. Mol. Med. 30, 71. https:\/\/doi.org\/10.1186\/s10020-024-00824-9 (2024).","journal-title":"Mol. Med."},{"key":"93844_CR7","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"A World Medical","year":"2013","unstructured":"World Medical, A. World medical association declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 310, 2191\u20132194 (2013).","journal-title":"JAMA"},{"key":"93844_CR8","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1006\/exer.1996.0020","volume":"62","author":"KC Dunn","year":"1996","unstructured":"Dunn, K. C., Aotaki-Keen, A. E., Putkey, F. R. & Hjelmeland, L. M. ARPE-19, a human retinal pigment epithelial cell line with differentiated properties. Exp. Eye Res. 62, 155\u2013169 (1996).","journal-title":"Exp. Eye Res."},{"key":"93844_CR9","doi-asserted-by":"publisher","first-page":"5961","DOI":"10.3390\/molecules28165961","volume":"28","author":"H Bardak","year":"2023","unstructured":"Bardak, H. et al. Selenium protects ARPE-19 and ACBRI 181 cells against high glucose-induced oxidative stress. Molecules 28, 5961. https:\/\/doi.org\/10.3390\/molecules28165961 (2023).","journal-title":"Molecules"},{"key":"93844_CR10","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/0002-9394(82)90197-0","volume":"94","author":"F Ferris","year":"1982","unstructured":"Ferris, F., Kassoff, A., Bresnick, G. & Bailey, I. New visual acuity charts for clinical research. Am. J. Ophthalmol. 94, 91\u201396 (1982).","journal-title":"Am. J. Ophthalmol."},{"key":"93844_CR11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1001\/archopht.1994.01090170074026","volume":"112","author":"EP Steinberg","year":"1994","unstructured":"Steinberg, E. P. et al. The VF-14: An index of functional impairment in patients with cataract. Arch. Ophthalmol. 112, 630\u2013638 (1994).","journal-title":"Arch. Ophthalmol."},{"key":"93844_CR12","doi-asserted-by":"publisher","unstructured":"Bakri, S. J., Wolfe, J. D., Regillo, C. D., Flynn, H. W. Jr & Wykoff, C. C. Evidence-based guidelines for management of diabetic macular edema. J Vitreoretin Dis. 3, 3 (2019). https:\/\/doi.org\/10.1177\/24741264198347111796-1806","DOI":"10.1177\/24741264198347111796-1806"},{"key":"93844_CR13","doi-asserted-by":"publisher","first-page":"e0222364","DOI":"10.1371\/journal.pone.0222364","volume":"14","author":"MY Choi","year":"2019","unstructured":"Choi, M. Y., Jee, D. & Kwon, J. W. Characteristics of diabetic macular edema patients refractory to anti-VEGF treatments and a dexamethasone implant. PLoS ONE. 14, e0222364. https:\/\/doi.org\/10.1371\/journal.pone.0222364 (2019).","journal-title":"PLoS One"},{"key":"93844_CR14","doi-asserted-by":"publisher","unstructured":"Hernaez-Ortega, M. C., Soto-Pedre, E. & Pini\u00e9s, J. A. Lanreotide autogel for persistent diabetic macular edema. Diabetes Res. Clin. Pract. 80 (e8-10). https:\/\/doi.org\/10.1016\/j.diabres.2008.02.007 (2008).","DOI":"10.1016\/j.diabres.2008.02.007"},{"key":"93844_CR15","doi-asserted-by":"publisher","unstructured":"Lacobini, C., Vitale, M., Pesce, C., Pugliese, G. & Menini, S. Diabetic complications and oxidative stress: A 20-Year voyage back in time and back to the future. Antioxidants 10 (727). https:\/\/doi.org\/10.3390\/antiox10050727 (2021).","DOI":"10.3390\/antiox10050727"},{"key":"93844_CR16","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1210\/er.2001-0039","volume":"23","author":"JL Evans","year":"2002","unstructured":"Evans, J. L., Goldfine, I. D., Maddux, B. A. & Grodsky, G. M. Oxidative stress and stress-Activated signaling pathways: A unifying hypothesis of type 2 diabetes. Endocr. Rev. 23, 599\u2013622. https:\/\/doi.org\/10.1210\/er.2001-0039 (2002).","journal-title":"Endocr. Rev."},{"key":"93844_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1007\/s11892-013-0384-x","volume":"13","author":"M Williams","year":"2013","unstructured":"Williams, M., Hogg, R. E. & Chakravarthy, U. Antioxidants and diabetic retinopathy. Curr. Diab Rep. 13, 481\u2013487 (2013).","journal-title":"Curr. Diab Rep."},{"key":"93844_CR18","doi-asserted-by":"publisher","first-page":"2902","DOI":"10.2337\/dc07-0332","volume":"30","author":"E Carrasco","year":"2007","unstructured":"Carrasco, E. et al. Lower somatostatin expression is an early event in diabetic retinopathy and is associated with retinal neurodegeneration. Diabetes Care. 30, 2902\u20132908 (2007).","journal-title":"Diabetes Care"},{"key":"93844_CR19","doi-asserted-by":"publisher","unstructured":"Sim\u00f3, R., Villarroel, M., Corraliza, L., Hern\u00e1ndez, C. & Garcia-Ram\u00edrez, M. The retinal pigment epithelium: Something more than a constituent of the blood-retinal barrier\u2013implications for the pathogenesis of diabetic retinopathy. J Biomed. Biotechnol. 190724; (2010). https:\/\/doi.org\/10.1155\/2010\/190724 (2010).","DOI":"10.1155\/2010\/190724"},{"key":"93844_CR20","doi-asserted-by":"publisher","first-page":"e001722","DOI":"10.1136\/bmjophth-2024-001722","volume":"9","author":"PAT Heutinck","year":"2024","unstructured":"Heutinck, P. A. T. et al. Somatostatin analogues as a treatment option for cystoid maculopathy in retinitis pigmentosa. BMJ Open. Ophthalmol. 9, e001722. https:\/\/doi.org\/10.1136\/bmjophth-2024-001722 (2024).","journal-title":"BMJ Open. Ophthalmol."},{"key":"93844_CR21","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.2337\/db12-0926","volume":"62","author":"C Hern\u00e1ndez","year":"2013","unstructured":"Hern\u00e1ndez, C. et al. Topical administration of somatostatin prevents retinal neurodegeneration in experimental diabetes. Diabetes 62, 2569\u20132578 (2013).","journal-title":"Diabetes"},{"key":"93844_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.3390\/ijms23031255","volume":"23","author":"Y-J Hsueh","year":"2022","unstructured":"Hsueh, Y-J. et al. The pathomechanism, antioxidant biomarkers, and treatment of oxidative stress-related eye diseases. Int. J. Mol. Sci. 23, 1255. https:\/\/doi.org\/10.3390\/ijms23031255 (2022).","journal-title":"Int. J. Mol. Sci."},{"key":"93844_CR23","doi-asserted-by":"publisher","first-page":"8760","DOI":"10.1073\/pnas.0902659106","volume":"106","author":"M Guma","year":"2009","unstructured":"Guma, M. et al. Genetic and Pharmacological Inhibition of JNK ameliorates hypoxia-induced retinopathy through interference with VEGF expression. Proc. Natl. Acad. Sci. U. S. A. 106, 8760\u20138765 (2009).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"93844_CR24","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1073\/pnas.1221729110","volume":"110","author":"H Du","year":"2013","unstructured":"Du, H. et al. JNK Inhibition reduces apoptosis and neovascularization in a murine model of age-related macular degeneration. Proc. Natl. Acad. Sci. U. S. A. 110, 2377\u20132382 (2013).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"93844_CR25","doi-asserted-by":"publisher","first-page":"457","DOI":"10.2337\/db18-0682","volume":"68","author":"R Sim\u00f3","year":"2019","unstructured":"Sim\u00f3, R. et al. Effects of topically administered neuroprotective drugs in early stages of diabetic retinopathy: Results of the EUROCONDOR clinical trial. Diabetes 68, 457\u2013463. https:\/\/doi.org\/10.2337\/db18-0682 (2019).","journal-title":"Diabetes"},{"key":"93844_CR26","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/j.ophtha.2011.02.048","volume":"118","author":"PA Pearson","year":"2011","unstructured":"Pearson, P. A. et al. Fluocinolone acetonide intravitreal implant for diabetic macular edema: A 3-year multicenter, randomized, controlled clinical trial. Ophthalmology 118, 1580\u20131587 (2011).","journal-title":"Ophthalmology"},{"key":"93844_CR27","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1016\/j.ophtha.2014.04.019","volume":"121","author":"J Cunha-Vaz","year":"2014","unstructured":"Cunha-Vaz, J. et al. Sustained delivery Fluocinolone acetonide vitreous implants: Long-term benefit in patients with chronic diabetic macular edema. Ophthalmology 121, 1892\u20131903 (2014).","journal-title":"Ophthalmology"},{"key":"93844_CR28","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1016\/j.ajo.2014.02.019","volume":"157","author":"O Comyn","year":"2014","unstructured":"Comyn, O. et al. A randomized trial to assess functional and structural effects of Ranibizumab versus laser in diabetic macular edema (the LUCIDATE study). Am. J. Ophthalmol. 157, 960\u2013970 (2014).","journal-title":"Am. J. Ophthalmol."},{"key":"93844_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/s10633-010-9219-0","volume":"120","author":"A Ozkiri\u015f","year":"2010","unstructured":"Ozkiri\u015f, A. Pattern electroretinogram changes after intravitreal bevacizumab injection for diabetic macular edema. Doc. Ophthalmol. 120, 243\u2013250 (2010).","journal-title":"Doc. Ophthalmol."},{"key":"93844_CR30","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1111\/j.1755-3768.2008.01438.x","volume":"88","author":"M L\u00f6vestam-Adrian","year":"2010","unstructured":"L\u00f6vestam-Adrian, M. & Holm, K. Multifocal electroretinography amplitudes increase after photocoagulation in areas with increased retinal thickness and hard exudates. Acta Ophthalmol. 88, 188\u2013192 (2010).","journal-title":"Acta Ophthalmol."},{"key":"93844_CR31","doi-asserted-by":"publisher","first-page":"5544","DOI":"10.1167\/iovs.13-11849","volume":"54","author":"M Sasaki","year":"2013","unstructured":"Sasaki, M. et al. Quantitative measurement of hard exudates in patients with diabetes and their associations with serum lipid levels. Invest. Ophthalmol. Vis. Sci. 54, 5544\u20135550 (2013).","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"93844_CR32","doi-asserted-by":"publisher","first-page":"620045","DOI":"10.3389\/fendo.2021.620045","volume":"12","author":"H Rao","year":"2021","unstructured":"Rao, H., Jalali, J. A., Johnston, T. P. & Koulen, P. Emerging roles of dyslipidemia and hyperglycemia in diabetic retinopathy: Molecular mechanisms and clinical perspectives. Front. Endocrinol. (Lausanne). 12, 620045. https:\/\/doi.org\/10.3389\/fendo.2021.620045 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"93844_CR33","doi-asserted-by":"publisher","first-page":"e15123","DOI":"10.1016\/j.heliyon.2023.e15123","volume":"9","author":"Y Shen","year":"2023","unstructured":"Shen, Y., Wang, H., Fang, J., Liu, K. & Xu, X. Novel insights into the mechanisms of hard exudate in diabetic retinopathy: Findings of serum lipidomic and metabolomics profiling. Heliyon 9, e15123. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e15123 (2023).","journal-title":"Heliyon"},{"key":"93844_CR34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s10792-017-0500-z","volume":"38","author":"S Yazgan","year":"2018","unstructured":"Yazgan, S., Arpaci, D., Celik, H. U. & Isik, I. Evaluation of macular and peripapillary choroidal thickness, macular volume and retinal nerve fiber layer in acromegaly patients. Int. Ophthalmol. 38, 617\u2013625 (2018).","journal-title":"Int. Ophthalmol."},{"key":"93844_CR35","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1007\/s40265-014-0283-8","volume":"74","author":"CB Burness","year":"2014","unstructured":"Burness, C. B., Dhillon, S. & Keam, S. J. Lanreotide autogel(\u00ae): A review of its use in the treatment of patients with acromegaly. Drugs 74, 1673\u20131691 (2014).","journal-title":"Drugs"},{"key":"93844_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1007\/s11102-010-0282-z","volume":"14","author":"M Fleseriu","year":"2011","unstructured":"Fleseriu, M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: A literature review. Pituitary 14, 184\u2013193 (2011).","journal-title":"Pituitary"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93844-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93844-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93844-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T13:53:02Z","timestamp":1742219582000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-93844-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["93844"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-93844-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"20 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"9157"}}